Table 2.
Percentage of patients receiving antibiotics and percentage of confirmed secondary infections.
| % Covid-19 patients treated with antibiotics | Confirmed secondary bacterial infection | Infecting agent (where reported) | Geographical location | References |
|---|---|---|---|---|
| 41/41 (100%) | 4/41 (10%) | – | Wuhan, China | [19] |
| 49/52 (94%) | 1/94 (1%) | K. pneumoniae | Wuhan, China | [50] |
| 26/53 (49%) | 16/53 (30%) | A. baumannii, Haemophilus influenza, P. aeruginosa, S. aureus, S. pneumoniae | Milan, Italy | [39] |
| 39/92 (42%) | 26/92 (28%) | A. baumannii, H. influenza, Moraxella catarrhalis, P. aeruginosa, S. aureus, S. pneumoniae | France | [31] |
| 181/191 (95%) | 28/191 (15%) | – | Wuhan, China | [18] |
| 143/150 (95%) | 12/150 (8%) | – | Wuhan China | [51] |
| 42/48 (88%) | 6/48 (13%) | E. faecium, H. influenza, P. aeruginosa | Vitoria, Spain | [40] |
| 37/298 (12%) | 30/298 (10%) | – | Shenzhen City, China | [52] |
| 319/476 (67%) | 35/410 (9%) | – | Wuhan, Shanghai, and Anhui (China) | [53] |
| 49/49 (100%) | 2/49 (4%) | Serratia sp., Enterobacter sp. | Hong Kong, China | [44] |
| 6/11(55%) | 6/11 (55%) | H. influenza, K. pneumoniae | Bangkok, Thailand | [41] |
| 66/67 (99%) | 3/28 (11%) | A. baumanii, Enterobacter cloacae | Wuhan, China | [43] |
| 1824/2536 (72%) | 190/1923 (10%) |